Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

Launched by 920TH HOSPITAL OF JOINT LOGISTICS SUPPORT FORCE OF PEOPLE'S LIBERATION ARMY OF CHINA · Apr 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CAR-T cell therapy for people with Chronic or Refractory Primary Immune Thrombocytopenia (ITP), a condition where the body doesn’t make enough platelets, which are important for blood clotting. This trial aims to see how effective and safe this therapy is for patients who have had ITP for over a year or have not responded well to standard treatments. The trial is open to men and women aged 8 to 75, and participants must be willing to follow the study rules and complete the necessary procedures.

If you or someone you know has ITP and meets the criteria, such as having a low platelet count and no other conditions that could cause this issue, you may be eligible to participate. During the trial, participants will receive CAR-T cell therapy and will be monitored for safety and effectiveness. It’s important to note that some people may not qualify due to specific health conditions or treatments. If you consider joining, you will work closely with the research team, who will ensure you understand the process and what to expect throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Willingness to complete the informed consent process and to comply with study procedures and visit schedule;
• • 2. Men and women aged 8-75;
• • 3. Participants diagnosed with chronic (\>12 months duration) or refractory (a documented intolerance or insufficient response to the first and second line standard treatment of ITP) ITP;
• • 4. The results of physical, instrumental, and laboratory examination of patients not suggest any disease which may cause thrombocytopenia other than ITP;
• • 5. Platelet count \<30 x 109 / L;
• • 6. If the patient is taking corticosteroids, the treatment regimen/dose should be stable (at least 2 weeks prior to screening);
• • 7. The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant;
• • 8. Willingness to use effective and reliable methods of contraception throughout the entire study period;
• Exclusion Criteria:
• • 1. All subjects with diseases which may cause secondary immune thrombocytopenia
• • 2. Patients with preventive splenectomy;
• • 3. Hemostatic disorders other than chronic thrombocytopenia;
• • 4. Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for \> 3 consecutive days within 2 weeks of the study start and until the end of the study;
• • 5. History of platelet agglutination abnormality that prevents reliable measurement of platelet counts;
• • 6. Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy;
• • 7. Grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment;
• • 8. History of thrombosis or presence of significant risk factors for thrombosis;
• • 9. Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system;
• • 10. Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal);
• • 11. Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex;
• • 12. Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study;
• • 13. Human immunodeficiency virus (HIV) seropositivity, Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive, Patients with hepatitis C (HCV-RNA quantitative test results positive), Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections;
• • 14. Patients with severe history of allergy or allergic constitution;
• • 15. Pregnancy and lactation;
• • 16. History of mental illness and known alcohol/drug addiction;
• • 17. Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan;
• • 18. Had undergone other clinical trials in the 4 weeks prior to participating in this trial;